Luspatercept versus mitapivat for non‐transfusion‐dependent β‐thalassemia: Dare to compare?
Khaled M. Musallam(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Alì Taher(American University of Beirut Medical Center), Antonis Kattamis, Maria Domenica Cappellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Kevin H.M. Kuo(University Health Network), Yeşim Aydınok(Ente Ospedaliero Ospedali Galliera), Vip Viprakasit(Siriraj Hospital), Sujit Sheth(Columbia University Irving Medical Center)
Cited by 5
Related Papers
Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study
|The Lancet|2011|1.3k
Thalassaemia
|The Lancet|2017|763
Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders
|Journal of Thrombosis and Haemostasis|2012|498
Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel
|Haematologica|2014|389
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320